У нас вы можете посмотреть бесплатно Steven Yeh, MD: The Promise of Suprachoroidal Injections или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
At the 36th annual meeting of the American Society of Retinal Specialists (ASRS) in Vancouver, British Columbia, MD Mag sat with Steven Yeh, MD, to discuss a novel method of drug delivery in ophthalmology: suprachoroidal injections. Traditionally, the treatments for conditions such as uveitis, include mostly intravitreal or periocular corticosteroid injections. While effective, they often carry a risk of adverse events, such as the development of cataracts and glaucoma. However, through work done at Emory University, Georgia Tech University, and Clearside Biomedical, this novel method has allowed for a more direct delivery of the medication. Additionally, Yeh noted that in early phase studies, suprachoroidal injections have been shown to be promising for both retinal vein occulusion and macular edema associated with diabetic retinopathy. Yeh also spoke about the highly discussed topic of treatment burden. While there are many paradigms for therapies in this space, they often involve the patient undergoing many intraocular injections, prompting the retinal community to seek any way that could change those conditions. Thus far, Yeh said as the community is learning more about suprachoroidal injections, they’ve found that, so far in retinal vein occlusion, they have shown an ability to reduce the number of injections patients need—indicating that they may be a favorable substitute.